To explore the composition of the immune cells in the tumor and peritumoral areas, the T cell marker CD3, the cytotoxic T cell marker CD8, and the macrophage/microglia marker CD68 were assessed in responders and non-responders (Additional file3: Table S7). This evidence concerns the gene CD8A and neoplasm.